> CALGB Results Summaries
CALGB Results Summaries
The Cancer and Leukemia Group B is working to make results of CALGB studies more accessible to those touched by cancer and others interested in cancer research in a reader-friendly format. Summaries highlight recently published results and provide resources for more details. To find summaries, search by type of cancer. 
Committee Short Cuts
CALGB 9840 - A phase III study of paclitaxel via weekly 1 hour infusion versus standard 3 hour infusion every 3 weeks with Herceptin (trastuzumab) (NSC #688097) in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer

CALGB 49907 - A randomized trial of adjuvant chemotherapy with standard regimens, cyclophosphamide,
methotrexate and fluorouracil – (CMF) or doxorubicin and cyclophosphamide – (AC), versus capecitabine in
women 65 years and older with node positive or node-negative breast cancer

Cancer Control and Health Outcomes
CALGB 70601 - Education as a predictor of survival in cancer clinical trials

CALGB 70602 - Individual and supra-individual effects in lung cancer clinical trial outcomes: A CALGB pilot analysis

Cancer in the Elderly

Correlative Sciences for Solid Tumors

CALGB 80303 - A randomized phase III trial of gemcitabine plus bevacizumab (NSC#704865 IND#7921) versus gemcitabine plus placebo in patients with advanced pancreatic cancer


CALGB 9720 - Phase III study of MDR modulation with PSC-833 (NSC # 648265) followed by immunotherapy with rIL-2 (NSC # 373364) vs no further therapy in previously untreated patients with AML > 60 years

Leukemia Correlative Sciences

CALGB 59804 - A phase I/II study of gemcitabine (Gemzar®)/ vinorelbine (Navelbine®)/liposomal doxorubicin (Doxil®) in relapsed/refractory Hodgkin's disease

Oncology Nursing

Pharmacology and Experimental Therapeutics
CALGB 60301 - Pharmacokinetic and phase I study of sorafenib (BAY 43-9006, NSC 724772, IND #69896) for solid tumors and hematologic malignancies in patients with hepatic or renal dysfunction

CALGB 30402—A phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib (NSC #681239, IND #58443) in advanced non–small-cell lung cancer patients with performance status (PS) 2



printer friendly
Copyright © CALGB 2004
All rights reserved
Last Modified: November 15, 2012
Contact the webmaster